Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Mitochondrial tyrosyl-DNA phosphodiesterase 2 and its TDP2S short isoform.

Huang SN, Dalla Rosa I, Michaels SA, Tulumello DV, Agama K, Khiati S, Jean SR, Baechler SA, Factor VM, Varma S, Murai J, Miller Jenkins LM, Kelley SO, Pommier Y.

EMBO Rep. 2018 Feb 9. pii: e42139. doi: 10.15252/embr.201642139. [Epub ahead of print]

PMID:
29438979
2.

Consecutive entosis stages in human substrate-dependent cultured cells.

Garanina AS, Kisurina-Evgenieva OP, Erokhina MV, Smirnova EA, Factor VM, Onishchenko GE.

Sci Rep. 2017 Oct 2;7(1):12555. doi: 10.1038/s41598-017-12867-6.

3.

Plasma glutamate carboxypeptidase is a negative regulator in liver cancer metastasis.

Lee JH, Cho HS, Lee JJ, Jun SY, Ahn JH, Min JS, Yoon JY, Choi MH, Jeon SJ, Lim JH, Jung CR, Kim DS, Kim HT, Factor VM, Lee YH, Thorgeirsson SS, Kim CH, Kim NS.

Oncotarget. 2016 Nov 29;7(48):79774-79786. doi: 10.18632/oncotarget.12967.

4.

Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress.

Gomez-Quiroz LE, Seo D, Lee YH, Kitade M, Gaiser T, Gillen M, Lee SB, Gutierrez-Ruiz MC, Conner EA, Factor VM, Thorgeirsson SS, Marquardt JU.

Toxicology. 2016 Jun 15;361-362:39-48. doi: 10.1016/j.tox.2016.07.004. Epub 2016 Jul 6.

5.

DNMT1 is a required genomic regulator for murine liver histogenesis and regeneration.

Kaji K, Factor VM, Andersen JB, Durkin ME, Tomokuni A, Marquardt JU, Matter MS, Hoang T, Conner EA, Thorgeirsson SS.

Hepatology. 2016 Aug;64(2):582-98. doi: 10.1002/hep.28563. Epub 2016 Apr 28.

PMID:
26999257
6.

Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype.

Matter MS, Marquardt JU, Andersen JB, Quintavalle C, Korokhov N, Stauffer JK, Kaji K, Decaens T, Quagliata L, Elloumi F, Hoang T, Molinolo A, Conner EA, Weber A, Heikenwalder M, Factor VM, Thorgeirsson SS.

Hepatology. 2016 Jun;63(6):1888-99. doi: 10.1002/hep.28487. Epub 2016 Mar 15.

7.

Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration.

Khiati S, Baechler SA, Factor VM, Zhang H, Huang SY, Dalla Rosa I, Sourbier C, Neckers L, Thorgeirsson SS, Pommier Y.

Proc Natl Acad Sci U S A. 2015 Sep 8;112(36):11282-7. doi: 10.1073/pnas.1511016112. Epub 2015 Aug 24.

8.

Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.

Won C, Kim BH, Yi EH, Choi KJ, Kim EK, Jeong JM, Lee JH, Jang JJ, Yoon JH, Jeong WI, Park IC, Kim TW, Bae SS, Factor VM, Ma S, Thorgeirsson SS, Lee YH, Ye SK.

Hepatology. 2015 Oct;62(4):1160-73. doi: 10.1002/hep.27968. Epub 2015 Aug 28.

9.

Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer.

Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, Pinna F, Lee YH, Kitade M, Domínguez MP, Castven D, Breuhahn K, Conner EA, Galle PR, Andersen JB, Factor VM, Thorgeirsson SS.

J Hepatol. 2015 Sep;63(3):661-9. doi: 10.1016/j.jhep.2015.04.018. Epub 2015 May 1.

10.

The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration.

Bae WK, Kang K, Yu JH, Yoo KH, Factor VM, Kaji K, Matter M, Thorgeirsson S, Hennighausen L.

FASEB J. 2015 May;29(5):1653-62. doi: 10.1096/fj.14-261537. Epub 2014 Dec 4.

11.

MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism.

Akita H, Marquardt JU, Durkin ME, Kitade M, Seo D, Conner EA, Andersen JB, Factor VM, Thorgeirsson SS.

Cancer Res. 2014 Oct 15;74(20):5903-13. doi: 10.1158/0008-5472.CAN-14-0527. Epub 2014 Sep 4.

12.

Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2.

Lee YH, Seo D, Choi KJ, Andersen JB, Won MA, Kitade M, Gómez-Quiroz LE, Judge AD, Marquardt JU, Raggi C, Conner EA, MacLachlan I, Factor VM, Thorgeirsson SS.

Cancer Res. 2014 Sep 1;74(17):4752-61. doi: 10.1158/0008-5472.CAN-13-3531. Epub 2014 Jun 23.

13.

CLPTM1L promotes growth and enhances aneuploidy in pancreatic cancer cells.

Jia J, Bosley AD, Thompson A, Hoskins JW, Cheuk A, Collins I, Parikh H, Xiao Z, Ylaya K, Dzyadyk M, Cozen W, Hernandez BY, Lynch CF, Loncarek J, Altekruse SF, Zhang L, Westlake CJ, Factor VM, Thorgeirsson S, Bamlet WR, Hewitt SM, Petersen GM, Andresson T, Amundadottir LT.

Cancer Res. 2014 May 15;74(10):2785-95. doi: 10.1158/0008-5472.CAN-13-3176. Epub 2014 Mar 19.

14.

Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits.

Marquardt JU, Seo D, Andersen JB, Gillen MC, Kim MS, Conner EA, Galle PR, Factor VM, Park YN, Thorgeirsson SS.

J Hepatol. 2014 Feb;60(2):346-353. doi: 10.1016/j.jhep.2013.10.014. Epub 2013 Oct 26.

15.

Epigenetic reprogramming modulates malignant properties of human liver cancer.

Raggi C, Factor VM, Seo D, Holczbauer A, Gillen MC, Marquardt JU, Andersen JB, Durkin M, Thorgeirsson SS.

Hepatology. 2014 Jun;59(6):2251-62. doi: 10.1002/hep.27026. Epub 2014 May 1.

16.

Loss of the nucleosome-binding protein HMGN1 affects the rate of N-nitrosodiethylamine-induced hepatocarcinogenesis in mice.

Postnikov YV, Furusawa T, Haines DC, Factor VM, Bustin M.

Mol Cancer Res. 2014 Jan;12(1):82-90. doi: 10.1158/1541-7786.MCR-13-0392. Epub 2013 Dec 2.

17.

Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling.

Kitade M, Factor VM, Andersen JB, Tomokuni A, Kaji K, Akita H, Holczbauer A, Seo D, Marquardt JU, Conner EA, Lee SB, Lee YH, Thorgeirsson SS.

Genes Dev. 2013 Aug 1;27(15):1706-17. doi: 10.1101/gad.214601.113.

18.

Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types.

Holczbauer A, Factor VM, Andersen JB, Marquardt JU, Kleiner DE, Raggi C, Kitade M, Seo D, Akita H, Durkin ME, Thorgeirsson SS.

Gastroenterology. 2013 Jul;145(1):221-31. doi: 10.1053/j.gastro.2013.03.013. Epub 2013 Mar 19.

19.

Biphasic regulation of the NADPH oxidase by HGF/c-Met signaling pathway in primary mouse hepatocytes.

Clavijo-Cornejo D, Enriquez-Cortina C, López-Reyes A, Domínguez-Pérez M, Nuño N, Domínguez-Meraz M, Bucio L, Souza V, Factor VM, Thorgeirsson SS, Gutiérrez-Ruiz MC, Gómez-Quiroz LE.

Biochimie. 2013 Jun;95(6):1177-84. doi: 10.1016/j.biochi.2013.01.005. Epub 2013 Jan 16.

20.

Loss of c-Met accelerates development of liver fibrosis in response to CCl(4) exposure through deregulation of multiple molecular pathways.

Marquardt JU, Seo D, Gómez-Quiroz LE, Uchida K, Gillen MC, Kitade M, Kaposi-Novak P, Conner EA, Factor VM, Thorgeirsson SS.

Biochim Biophys Acta. 2012 Jun;1822(6):942-51. doi: 10.1016/j.bbadis.2012.02.012. Epub 2012 Feb 22.

21.

Contribution of hepatic lineage stage-specific donor memory to the differential potential of induced mouse pluripotent stem cells.

Lee SB, Seo D, Choi D, Park KY, Holczbauer A, Marquardt JU, Conner EA, Factor VM, Thorgeirsson SS.

Stem Cells. 2012 May;30(5):997-1007. doi: 10.1002/stem.1074.

22.

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS.

Gastroenterology. 2012 Apr;142(4):1021-1031.e15. doi: 10.1053/j.gastro.2011.12.005. Epub 2011 Dec 13.

23.

Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice.

Ishikawa T, Factor VM, Marquardt JU, Raggi C, Seo D, Kitade M, Conner EA, Thorgeirsson SS.

Hepatology. 2012 Apr;55(4):1215-26. doi: 10.1002/hep.24796.

24.

Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer.

Coulouarn C, Factor VM, Conner EA, Thorgeirsson SS.

Carcinogenesis. 2011 Oct;32(10):1434-40. doi: 10.1093/carcin/bgr133. Epub 2011 Jul 18.

25.

Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways.

Marquardt JU, Raggi C, Andersen JB, Seo D, Avital I, Geller D, Lee YH, Kitade M, Holczbauer A, Gillen MC, Conner EA, Factor VM, Thorgeirsson SS.

Hepatology. 2011 Sep 2;54(3):1031-42. doi: 10.1002/hep.24454. Epub 2011 Jul 27.

26.

Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response.

Lee YH, Judge AD, Seo D, Kitade M, Gómez-Quiroz LE, Ishikawa T, Andersen JB, Kim BK, Marquardt JU, Raggi C, Avital I, Conner EA, MacLachlan I, Factor VM, Thorgeirsson SS.

Oncogene. 2011 Oct 6;30(40):4175-84. doi: 10.1038/onc.2011.126. Epub 2011 Apr 18.

27.

Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer.

Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, Thorgeirsson SS.

J Hepatol. 2011 Feb;54(2):311-9. doi: 10.1016/j.jhep.2010.06.036. Epub 2010 Sep 7.

28.

An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer.

Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA, Thorgeirsson SS.

Sci Transl Med. 2010 Oct 20;2(54):54ra77. doi: 10.1126/scitranslmed.3001338.

29.

Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma.

Lee YH, Andersen JB, Song HT, Judge AD, Seo D, Ishikawa T, Marquardt JU, Kitade M, Durkin ME, Raggi C, Woo HG, Conner EA, Avital I, Maclachlan I, Factor VM, Thorgeirsson SS.

Cancer Res. 2010 Nov 1;70(21):8264-9. doi: 10.1158/0008-5472.CAN-10-0749. Epub 2010 Oct 19.

30.

Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice.

Factor VM, Seo D, Ishikawa T, Kaposi-Novak P, Marquardt JU, Andersen JB, Conner EA, Thorgeirsson SS.

PLoS One. 2010 Sep 16;5(9). pii: e12739. doi: 10.1371/journal.pone.0012739.

31.

Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.

Marquardt JU, Factor VM, Thorgeirsson SS.

J Hepatol. 2010 Sep;53(3):568-77. doi: 10.1016/j.jhep.2010.05.003. Epub 2010 May 31. Review.

32.

Progenitor-derived hepatocellular carcinoma model in the rat.

Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A, Thorgeirsson SS.

Hepatology. 2010 Apr;51(4):1401-9. doi: 10.1002/hep.23488.

33.

Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties.

Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS.

Oncogene. 2009 Oct 8;28(40):3526-36. doi: 10.1038/onc.2009.211. Epub 2009 Jul 20.

34.

Recurrent and nonrandom DNA copy number and chromosome alterations in Myc transgenic mouse model for hepatocellular carcinogenesis: implications for human disease.

Zimonjic DB, Ullmannova-Benson V, Factor VM, Thorgeirsson SS, Popescu NC.

Cancer Genet Cytogenet. 2009 May;191(1):17-26. doi: 10.1016/j.cancergencyto.2008.12.014.

35.

Central role of c-Myc during malignant conversion in human hepatocarcinogenesis.

Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C, Conner EA, Factor VM, Roskams T, Thorgeirsson SS.

Cancer Res. 2009 Apr 1;69(7):2775-82. doi: 10.1158/0008-5472.CAN-08-3357. Epub 2009 Mar 10. Erratum in: Cancer Res. 2009 Apr 15;69(8):3721. Coulouarn, Cedric [added].

36.

E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.

Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS.

Gastroenterology. 2008 Oct;135(4):1322-32. doi: 10.1053/j.gastro.2008.07.012. Epub 2008 Jul 17.

37.

Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer.

Coulouarn C, Factor VM, Thorgeirsson SS.

Hepatology. 2008 Jun;47(6):2059-67. doi: 10.1002/hep.22283.

38.

Deletion of the Met tyrosine kinase in liver progenitor oval cells increases sensitivity to apoptosis in vitro.

del Castillo G, Factor VM, Fernández M, Alvarez-Barrientos A, Fabregat I, Thorgeirsson SS, Sánchez A.

Am J Pathol. 2008 May;172(5):1238-47. doi: 10.2353/ajpath.2008.070793. Epub 2008 Apr 1.

39.

Hepatocyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis.

Gómez-Quiroz LE, Factor VM, Kaposi-Novak P, Coulouarn C, Conner EA, Thorgeirsson SS.

J Biol Chem. 2008 May 23;283(21):14581-9. doi: 10.1074/jbc.M707733200. Epub 2008 Mar 18.

40.

Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis.

Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, Factor VM, Thorgeirsson SS.

Cancer Res. 2007 Oct 15;67(20):9844-51.

41.

Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS.

J Clin Invest. 2007 Sep;117(9):2713-22.

42.

Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver.

Heo J, Factor VM, Uren T, Takahama Y, Lee JS, Major M, Feinstone SM, Thorgeirsson SS.

Hepatology. 2006 Dec;44(6):1478-86.

PMID:
17133486
43.

Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis.

Coulouarn C, Gomez-Quiroz LE, Lee JS, Kaposi-Novak P, Conner EA, Goldina TA, Onishchenko GE, Factor VM, Thorgeirsson SS.

Hepatology. 2006 Oct;44(4):1003-11.

PMID:
17006931
44.

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.

Kaposi-Novak P, Lee JS, Gòmez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS.

J Clin Invest. 2006 Jun;116(6):1582-95. Epub 2006 May 18.

45.

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS.

Gastroenterology. 2006 Apr;130(4):1117-28.

PMID:
16618406
46.

Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice.

Novoselov SV, Calvisi DF, Labunskyy VM, Factor VM, Carlson BA, Fomenko DE, Moustafa ME, Hatfield DL, Gladyshev VN.

Oncogene. 2005 Dec 1;24(54):8003-11.

PMID:
16170372
47.
48.

Activation of the canonical Wnt/beta-catenin pathway confers growth advantages in c-Myc/E2F1 transgenic mouse model of liver cancer.

Calvisi DF, Conner EA, Ladu S, Lemmer ER, Factor VM, Thorgeirsson SS.

J Hepatol. 2005 Jun;42(6):842-9. Epub 2005 Apr 8.

PMID:
15885355
49.

Vitamin E down-modulates iNOS and NADPH oxidase in c-Myc/TGF-alpha transgenic mouse model of liver cancer.

Calvisi DF, Ladu S, Hironaka K, Factor VM, Thorgeirsson SS.

J Hepatol. 2004 Nov;41(5):815-22.

PMID:
15519655
50.

Regulation of alpha-fetoprotein by nuclear factor-kappaB protects hepatocytes from tumor necrosis factor-alpha cytotoxicity during fetal liver development and hepatic oncogenesis.

Cavin LG, Venkatraman M, Factor VM, Kaur S, Schroeder I, Mercurio F, Beg AA, Thorgeirsson SS, Arsura M.

Cancer Res. 2004 Oct 1;64(19):7030-8.

Supplemental Content

Loading ...
Support Center